CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS) today announced the closing of its initial public offering of 4,600,000 shares of common stock at an offering price of $12.50 per share, including 600,000 shares of common stock issued upon the full exercise by the underwriters of their option to purchase additional shares. All of the shares in the offering were sold by Syros. The gross proceeds from the initial public offering were approximately $57.5 million, before underwriting discounts, commissions and estimated offering expenses. The Company’s common stock is listed on the NASDAQ Global Select Market under the ticker symbol “SYRS.”

Cowen and Company and Piper Jaffray & Co. acted as joint book-running managers for the offering. JMP Securities acted as lead manager for the offering, and Wedbush PacGrow acted as co-manager for the offering.

A registration statement relating to these securities was filed with, and was declared effective by, the Securities and Exchange Commission on June 29, 2016. Copies of the registration statement can be accessed by visiting the Securities and Exchange Commission website at This offering was made only by means of a written prospectus forming part of the effective registration statement. A copy of the final prospectus relating to the offering was filed with the Securities and Exchange Commission and may be obtained from Cowen and Company LLC, c/o Broadbridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, by telephone at (631) 274-2806 or by fax at (631) 254-7140, and from Piper Jaffray & Co., by mail at Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924 or by email at

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Syros Pharmaceuticals
Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations.

Media Contact:
Ten Bridge Communications, Inc.
Naomi Aoki, 617-283-4298
Investor Contact:
Stern Investor Relations, Inc.
Jesse Baumgartner, 212-362-1200

Source: Syros Pharmaceuticals